Nikon Corp

Good afternoon, everyone. I am Muneaki Tokunari, President of Nikon Corporation. Thank you very much for taking time to join us today. I will explain the progress of our medium-term management plan. Please look at slide 3. The current medium-term management plan spans a period of four years, and we now have one and a half years to go. As stated at the bottom of the slide, our performance in areas other than The imaging products business is behind our expectations in terms of earnings. The recovery in demand for semiconductor-related business has been slower than expected, and the situation remains difficult, but we will work on measures to restore profitability, including self-help efforts from the second half of the year onwards. On the other hand, since I took office as President in April, I have also started to strengthen the management base with the aim of achieving our Vision 2030, and we have already seen some results in our growth strategy. Today, I will report on these, among others. First, I will explain the progress in each of the five business segments using slide 4. For the figures shown on the left, I will rely on the presentation from Deputy CFO Omura later, And I will talk about the main business topics on the right. In imaging products business, we completed in April the acquisition of RED, a specialist manufacturer of cinema cameras, which will form the core of our future video strategy. In the components business, we have also begun restructuring of the former industrial metrology business. We expect to incur one-time expenses of around 2.5 billion yen in the second half, but from next fiscal year onwards, we expect to see an improvement in operating profit of around mid-1 billion yen range. Slide 5 summarizes the progress we have made in building the management base for future growth. Among these in manufacturing, shown second from the bottom, a new headquarters building and innovation center was launched, which consolidate R&D functions and enable diverse work styles. A new building at METO plant, which was built to expand production capacity in the components business, was completed in August. Please move to slide 6. This slide shows the progress of the five growth drivers required to enhance future corporate value of Nikon set out in the medium-term management plan. Regarding the contract cell manufacturing, or CDMO, for the healthcare business, the number of cell therapies moving from clinical trials to commercialization has increased, and this has grown to become a business with close to 1 billion yen in operating profit for this fiscal year. We plan to grow it even further to make it into one of the future pillars of earnings. In the precision equipment business, we have started developing digital lithography system for advanced packaging, which is expected to expand in line with the development of AI, and we plan to fully enter the back-end process. Deputy CFO Omura will explain these in more detail later. Please turn to slide 7. In the basic policy on management that is conscious of cost of capital and stock price that we announced in May 2023, we clarified our policy of dividends of 60 yen per share in the final year of the medium-term management plan and additional share buyback of 30 billion yen or more during its period. Based on this policy, on October 31st, we announced that we would be buying back and cancel shares worth up to 30 billion yen which is 8.7% of the total number of shares issued. Furthermore, in order to ensure that this share buyback will not affect growth investments such as R&D and capital investments, we plan to use the proceeds from the sale of cross-share holdings to fund this. As I said, we are currently challenged with our performance, but we will steadily promote the policies set out in our medium-term management plan such as improving our management base and developing growth drivers with the aim of becoming a company that supports a society where humans and machines co-create seamlessly, expected to arrive in 2030. We ask you as shareholders and investors for continued understanding and support. I am Yasuhiro Omura, Deputy CFO. I'll explain the first half financial results and the full year forecast. First, the key points of the first half financial results. Revenue was 332.7 billion yen, operating profit was 5.8 billion yen, and the profit attributable to owners of the parent was 2.9 billion yen. Compared to the first half of the previous year, revenue increased by 1.5 billion yen. Although sales of semiconductor lithography systems and EUV-related components decreased, sales of digital cameras and FPD lithography systems increased, and together with weaker EM, the total revenue increased. As for profit, in addition to decreased revenue from semiconductor lithography systems and EUV-related components, one of expenses for relocation of the head office pushed down profit. Compared to the previous forecast announced in August, In addition to the downside due to the postponement of sales of semiconductor-related products, profit attributable to owners of parent was significantly behind, affected by exchange rate fluctuations, which caused the valuation of foreign currency-denominated assets to fall due to forex conversion, leading to increased forex losses and losses on valuation of investment securities. Slide 10 shows the main consolidated figures for the first half that I just explained, and comparisons to the year-before results and August forecasts. The free cash flow, which was deeply negative in the previous year, has improved. This is because, despite the costs related to the acquisition of RED and the new head office, operating cash flow turned significantly positive, mainly due to increased advance payments received. Slide 11 shows consolidated revenue and profit and loss for the three months from July to September. Operating cash flow for the second quarter was positive for the fourth consecutive quarter, and free cash flow was also positive at 7.8 billion yen. Slide 12 shows the results by segment for the first half. In the yellow boxes, the top row shows revenue and the bottom row shows operating profit for each segment. I will explain the details for each segment. First on the imaging products business. Revenue increased by 14.1 billion yen year-on-year to 151.7 billion yen, and operating profit increased by 3.6 billion yen to 28.8 billion yen. Due to strong sales of mirrorless cameras Z8 and ZF, as well as the launch of the new Z6 III, sales volume of digital cameras interchangeable lens type increased by 20,000 units year-on-year to 410,000, and interchangeable lenses increased by 40,000 to 650,000 units. The operating profit margin was 19% up year-on-year, partly due to the weaker EM. Compared to the previous forecast in August, operating profit was higher due to the weaker EM, improvements in the product mix, and postponement of some expenses. Slide 14 shows the precision equipment business. Revenue decreased by 14.5 billion yen year-on-year to 81.5 billion yen, and operating profit decreased by 2.3 billion yen to 0.9 billion yen. In FPD lithography systems, due to the recovery in the panel market, capital investments in high-resolution panels increased, and sales volume increased significantly from 4 units in the previous year to 16. On the other hand, sales volume of new semiconductor lithography systems fell significantly from 11 units in the previous year to 4 due to the impact of customers cutting back on investments and some installations being postponed to the second half. Overall, the precision equipment business dropped in both revenue and profit as the increased sales in FPD lithography systems slide 15 shows the healthcare business. Revenue increased by 3.9 billion yen year-on-year to 55.1 billion yen. In the second quarter, sales of eye care solutions grew, particularly in Europe, and revenue increased in the first half even when excluding the effects of the weaker yen. Offering profit, on the other hand, decreased by 1.4 billion yen year-on-year to 1.3 billion yen due to an increase in upfront investments such as R&D expenses. Slide 16 shows the components business. Due to the impact of the delayed recovery in the semiconductor and factory automation markets, sales of EUV-related components and encoders decreased, and both revenue and profit decreased year on year. In addition, due to the delay in the market recovery, the business environment in the second quarter remained challenging and demand did not recover. The previous forecast in August was missed due to postponed sales of EUV-related components and reduced sales of encoders. Slide 17 shows the distal manufacturing business. Sales increased significantly by 42% year-on-year due to strong sales of NXG series large format metal 3D printers from SLM Solutions. In addition to the increased revenue at SLM Solutions, The disappearance of one-time costs of restructuring recorded in the previous year, as well as the cost reductions, also contributed to reduction in the operating loss. Next, I will explain the full-year forecast. We have revised down our revenue forecast by 25 billion yen to 725 billion yen due to the postponement of customer investments which has shifted sales of related products in the semiconductor lithography and components business into the next fiscal year or later. Operating profit has been revised downward by 13 billion yen to 22 billion yen, with the imaging product business revised upward by 2 billion yen, while precision equipment, healthcare, and components businesses being revised downward by 6 billion, 2 billion, and 9 billion yen, respectively. the forecast for profit attributable to owners or parent has been revised downward by 14 billion yen to 16 billion yen. But with regard to shareholder returns, the interim dividend will be 25 yen per share and the annual dividend will be increased by 5 yen to 55 yen per share as previously forecasted. In addition, As President Okunari said earlier, we will perform share buyback after a maximum of 30 billion yen. The exchange rates for the second half are unchanged from the previous forecast at 145 yen to the dollar and 155 yen to the euro. Slide 20 shows the changes in the operating profit forecast from the announcement in August. The main factor behind the downward revision was a 12.5 billion yen decrease in revenue due to postponed sales in the precision equipment and the components businesses. In addition, there was a total of 3.5 billion yen one-time costs for the restructuring of the former industrial meteorology business, which is included in the components business, and for the healthcare business. Please refer to slide 21. The main figures for the full-year forecast are shown in a table, including year-on-year and previous forecast comparisons. The overview has already been explained. Slide 22 shows a list of full-year forecasts by segment, including year-on-year and previous forecast comparisons. I will explain the details for each segment. First, the imaging products business. The forecast for revenue remains unchanged from August at 305 billion yen. We plan to launch Z52 this month, following the Z63 in June, leveraging the cutting edge functions of Z9. We will continue to strengthen our mirrorless camera product lineup. We have raised our operating profit forecast by 2 billion yen from August, based on the first half results. Compared to the previous year, we expect to see an increase in operating profit of 0.5 billion yen to 47 billion yen due to an increase in profit from the expansion of the strong mirrorless camera business offsetting the expected increase in expenses such as acquisition-related costs for RED, which we acquired in April, and R&D costs. Slide 24 shows the forecast for the precision equipment business. Please look at the bottom left. Due to the delay in the market recovery, some customers have postponed their investments, resulting in the postponement of delivery, and sales volume of semiconductor lithography systems is expected to decrease by 7 units to 28. In addition, the sales volume of FPD lithography systems is expected to be 38 units, as installation of one unit will be delayed until the next fiscal year. Affecting these changes in sales volume, we have lowered our revenue forecast by 20 billion yen from August to 195 billion yen. Compared to the previous year, while we expect a significant increase in sales of FPD lithography systems for high-resolution panels, this will not be enough to offset The decrease in sales of ARF lithography systems and the revenue of the entire precision equipment business will decrease. Operating profit has been revised down by 6 billion yen from the forecast in August to 9 billion yen due to declined revenue. Please refer to slide 25. I'd like to briefly discuss the digital lithography system for advanced semiconductor packaging applications that we announced last month. Our digital lithography systems will respond to the increasing sophistication and diversification of semiconductors due to the progress of AI. We plan to launch this product in fiscal year 2026, targeting the large-scale chiplet market for data centers where the miniaturization of wiring patterns and the increase in package size are progressing by combining the digital lithography technology, high resolution technology for semiconductor lithography systems that we have developed to date, and high productivity of the multi-projection lens technology for FPD lithography systems. Please turn to slide 26. I will now explain the healthcare business. In life science solutions, We are concerned about the impact on the revenue of persistently high interest rates in the U.S. and economic downturn in China, but we aim to achieve our forecast by developing the private sector market and strengthening our drug discovery support services. In eye care solutions, we expect to see year-on-year revenue growth due to demand from optometrists and major chains in Europe and the U.S., Operating profit is expected to be 2 billion yen lower than the August forecast due to lower than expected sales in life science solutions caused by the delay in the market recovery and additional 1 billion yen in one-time expenses related to IKEA solutions. Revenue from contract sale manufacturing is expected to increase year-on-year due to expanded orders. As the third pillar of the healthcare business, it has entered the stage of sustained profit contribution. Please refer to slide 27. I will give a brief introduction to our contract cell manufacturing business. Nikon Cell Innovation, a wholly owned subsidiary, started its business in 2015 through a strategic alliance with Lonza, the world's largest contract manufacturer, and has grown into Japan's largest regenerative medicine, CDMO. In the area of contract manufacturing of cell therapies utilizing living cells, we already have around 10 projects underway, either in commercialization or clinical trials, with revenue in several billions of yen and operating profit close to 1 billion yen. And we expect further increases in both revenue and profit in the next fiscal year. Slide 28 shows the components business. Although there are signs of a bottoming out in some areas of the semiconductor and factory automation markets, we do not expect to see the kind of recovery in demand that we had initially projected due to the customers postponing their investments. In the semiconductor-related field, sales of EUV-related components have been delayed, and sales of video measuring systems used in backend processes have decreased, and sales of encoders for factory automation are expected to decrease. In light of this, we have lowered our revenue forecast by 7 billion yen from August to 78 billion yen. On the other hand, sales of large X-ray systems for the aerospace industry are progressing steadily, and we are also steadily winning orders for semiconductor-related optical components by adding customers. Operating profit has been revised down by 9 billion yen from August to 8 billion yen due to the impact of the decrease in revenue, and recognition of 2.5 billion yen in restructuring-related expenses in the former industrial meteorology business, which is now included in the components business. The Industrial Solutions Business Unit, newly established this fiscal year, has decided to implement restructurings of the former industrial meteorology business that has been integrated into the business unit, such as the transfer of the 3D laser scanner business and headcount reduction in order to optimize the organization by reviewing the strategies by product and by region. We will implement the necessary measures during this fiscal year and expect to see an improvement in operating profit from the next fiscal year onwards. Slide 29 shows the distal manufacturing business. Both revenue and operating profit remain unchanged from the previous forecast in August. Due to increased demand in aerospace and defense industries, orders and sales are progressing steadily, centered on the NXG series of large-format metal 3D printers from SLM Solutions. This fiscal year, we aim to turn SLM Solutions profitable on a standalone four-year EBITDA basis. There is no change to our policy of aiming for operating-level profitability on an SLM solution standalone basis in the next fiscal year, and to turn profitable for the entire digital manufacturing business in March 2027. That concludes my explanation. In summary, the first half saw results fall short of expectations due to postponement in semiconductor lithography systems and EUV-related components. The four-year forecast has been revised down by ¥25 billion to ¥725 billion in revenue and by ¥13 billion to ¥22 billion in operating profit. Although it is still difficult to predict the investment trends of semiconductor-related customers, or the recovery of demand for related products, we will continue to minimize the impact of market deterioration by making timely and appropriate resource investments through close communication with customers. And we will also strive not to miss the timing of the market recovery. In addition, we will implement necessary measures such as restructuring of the former industrial metrology business quickly and aim to further expand growth drivers through efficient R&D investments leading to a recovery in business performance from the next fiscal year onwards. We would like to ask for your continued understanding and support from shareholders and investors. Thank you for your attention.